264 related articles for article (PubMed ID: 15640791)
1. Engineered single chain antibody fragments for radioimmunotherapy.
Huhalov A; Chester KA
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):279-88. PubMed ID: 15640791
[TBL] [Abstract][Full Text] [Related]
2. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.
Wittel UA; Jain M; Goel A; Chauhan SC; Colcher D; Batra SK
Nucl Med Biol; 2005 Feb; 32(2):157-64. PubMed ID: 15721761
[TBL] [Abstract][Full Text] [Related]
3. Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers.
Albrecht H; Denardo GL; Denardo SJ
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):304-13. PubMed ID: 17464275
[TBL] [Abstract][Full Text] [Related]
4. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
Lin Y; Pagel JM; Axworthy D; Pantelias A; Hedin N; Press OW
Cancer Res; 2006 Apr; 66(7):3884-92. PubMed ID: 16585217
[TBL] [Abstract][Full Text] [Related]
5. Tailor-made antibody therapeutics.
Chowdhury PS; Wu H
Methods; 2005 May; 36(1):11-24. PubMed ID: 15848071
[TBL] [Abstract][Full Text] [Related]
6. Effects of genetic engineering on the pharmacokinetics of antibodies.
Colcher D; Goel A; Pavlinkova G; Beresford G; Booth B; Batra SK
Q J Nucl Med; 1999 Jun; 43(2):132-9. PubMed ID: 10429508
[TBL] [Abstract][Full Text] [Related]
7. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics.
Weisser NE; Hall JC
Biotechnol Adv; 2009; 27(4):502-20. PubMed ID: 19374944
[TBL] [Abstract][Full Text] [Related]
8. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (Intrabody).
Heng BC; Cao T
Med Hypotheses; 2005; 64(6):1105-8. PubMed ID: 15823695
[TBL] [Abstract][Full Text] [Related]
9. Generation of functional scFv intrabodies for triggering anti-tumor immunity.
Bonnin E; Gruel N; Moutel S; Mantegazza AR; Barrio MM; Mordoh J; Teillaud JL
Methods; 2004 Oct; 34(2):225-32. PubMed ID: 15312675
[TBL] [Abstract][Full Text] [Related]
10. One-step on-column purification and refolding of a single-chain variable fragment (scFv) antibody against tumour necrosis factor alpha.
Liu M; Wang X; Yin C; Zhang Z; Lin Q; Zhen Y; Huang H
Biotechnol Appl Biochem; 2006 Mar; 43(Pt 3):137-45. PubMed ID: 16293104
[TBL] [Abstract][Full Text] [Related]
11. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.
Deyev SM; Lebedenko EN
Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269
[TBL] [Abstract][Full Text] [Related]
12. Cloning, expression and characterisation of a single-chain Fv antibody fragment against domoic acid in Escherichia coli.
Hu X; O'Dwyer R; Wall JG
J Biotechnol; 2005 Oct; 120(1):38-45. PubMed ID: 16019098
[TBL] [Abstract][Full Text] [Related]
13. Design and manufacture of monoclonal antibodies for radioimmunotherapy.
Hale G; Berrie E; Bird P
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):258-66. PubMed ID: 15640789
[TBL] [Abstract][Full Text] [Related]
14. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
Shankar S; Vaidyanathan G; Kuan CT; Bigner DD; Zalutsky MR
Nucl Med Biol; 2006 Jan; 33(1):101-10. PubMed ID: 16459265
[TBL] [Abstract][Full Text] [Related]
15. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
Albrecht H; Denardo GL; Denardo SJ
J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921
[TBL] [Abstract][Full Text] [Related]
16. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation.
Stoll P; Bassler N; Hagemeyer CE; Eisenhardt SU; Chen YC; Schmidt R; Schwarz M; Ahrens I; Katagiri Y; Pannen B; Bode C; Peter K
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1206-12. PubMed ID: 17322097
[TBL] [Abstract][Full Text] [Related]
17. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.
Reiter Y; Brinkmann U; Lee B; Pastan I
Nat Biotechnol; 1996 Oct; 14(10):1239-45. PubMed ID: 9631086
[TBL] [Abstract][Full Text] [Related]
18. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis.
Knogler K; Grünberg J; Zimmermann K; Cohrs S; Honer M; Ametamey S; Altevogt P; Fogel M; Schubiger PA; Novak-Hofer I
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):603-11. PubMed ID: 17255283
[TBL] [Abstract][Full Text] [Related]
19. [Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer].
Wang Y; Li X; Chen W
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):16-21. PubMed ID: 16495168
[TBL] [Abstract][Full Text] [Related]
20. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
